Genetic Medicines

Shaping the RNA Century

6

Patent Families Across Core Technologies

75+

Filed U.S. & International Patent Applications

Transforming Medicine

Powering the Promise of Genetic Medicines

Alloy Genetic Medicines is positioned to lead the RNA Century, where AI-programmable sequences, precise delivery, potency, and patient safety define what’s possible. Continually strengthening our position as a leading collaborator for teams discovering and developing RNA therapeutics and DNA-editing gene therapy constructs, we continue to assemble the platforms, enabling technology, and world-leading expertise needed to unlock solutions for previously undruggable targets.

Discovery & Development

Foundational Infrastructure and Expertise for Genetic Medicine Discovery and Development

To advance the discovery and development of RNA-based medicines, Alloy Genetic Medicines provides the proprietary platforms, advanced technologies, and collaborative ecosystem needed to redefine therapeutic possibilities.

Ground-Breaking Platforms

Alloy’s AntiClastic™ Cyclic Oligonucleotide platform facilitates the design of conformationally constrained, transiently circular molecules that enhance potency and reduce inflammatory signaling compared with first-generation linear oligonucleotides.

Advanced Enabling Technology

Using a sophisticated hybrid of AI modeling, machine learning, and human expertise, our Oligonucleotide Design Studio rapidly screens hundreds of thousands of sequences in silico. Our approach optimizes target affinity and developability, accelerating the discovery process and providing a faster line of sight to IND filing.

Innovation Ecosystem

Our RNA innovation ecosystem empowers the global scientific community to develop genetic medicines. With partners in academia, biotechs, and the largest biopharma organizations, Alloy democratizes access to tools, technologies, services, capabilities, and company-creation resources foundational to advancing the discovery and development of genetic medicines.

Therapeutic Index

Reshaping Oligonucleotide Architectures Boosts Potency, Stability, Precision, and Patient Safety

By moving beyond linear designs to engineered cyclic architectures, Alloy elevates oligonucleotide medicines, delivering higher potency, reduced immunogenicity, and precise, durable control of gene expression.

The AntiClastic Cyclic Oligonucleotide Platform Is Uniquely Capable of Supporting ASO and siRNA Opportunities

The AntiClastic platform transforms oligonucleotide therapeutic concepts into IP-protected, clinic-ready assets through a comprehensive collaboration. We are uniquely positioned as the only platform accessible to the market that engineers antisense oligonucleotides (ASOs), siRNAs, and sgRNAs into proprietary cyclic architectures.

Our teams deliver AI-driven design and lead identification, lead optimization and development, and drug candidate nomination to accelerate discovery programs, democratizing access to transformative, high-potency RNA innovation for global developers.

Patented Anticlastic Architectures Enable Wide-Ranging Applications

Proprietary anticlastic cyclic architectures unlock modalities that enable a range of functions in genetic medicines, including targeted RNA degradation, splice modulation, gene editing and regulation, DNA modulation, ADAR editing, gene expression modulation, and more.

Drug Candidate Innovation

Advancing Novel Therapeutic Solutions

From molecule design to the clinic, we align rigorous QbD development with world-class scientific leadership to turn high-potential RNA concepts into manufacturable, scalable therapeutic solutions.

Early Development with Manufacturability at the Forefront

We utilize risk-based, Quality-by-Design frameworks from the start to ensure drug candidates can be manufactured and successfully scaled to the clinic.

Critical Quality Attribute (CQA)-based process and analytical development

Tech transfer packages that de-risk CMC and IND submissions

The AntiClastic Cyclic Oligonucleotide Platform Is Uniquely Capable of Supporting ASO and siRNA Opportunities

Resources

Press Releases

Alloy Therapeutics Enters into Multi-Target Collaboration and License Agreement with Biogen for Use of Alloy’s AntiClastic™ ASO Platform

Poster

Poster | Transient Cyclic Structured Oligonucleotides

Perspectives

Rethinking Antisense Architecture with Transient Cyclic Oligonucleotides for Next-Generation RNA Therapeutics

Press Releases

Alloy Therapeutics Appoints Christian Cobaugh, Ph.D., as CEO of Alloy Genetic Medicines

Press Releases

Alloy Therapeutics Launches Proprietary AntiClastic™ Antisense Oligonucleotide Platform to Make Potent Genetic Medicine

Join Us in Shaping the RNA Century

Whether you are a global pharma leader, biotech, academic team, or other industry stakeholder, partner with Alloy Genetic Medicines to deliver next-generation genetic medicines to patients who need them.

```html

```